First-line hepatitis C therapy which includes a protease inhibitor can be cost-effective, investigators show in the Annals of Internal Medicine. The study showed that a triple combination of drugs including the cheaper of the newly-licensed protease inhibitors was most cost effective after screening for a gene associated with response to hepatitis C treatment and for patients with advanced fibrosis.
“Our study supports the important role of protease inhibitors in treating chronic HCV [hepatitis C virus] for patients with advanced fibrosis as part of a first-line regimen,” write the authors.
Read more....
1 comments:
It's good to know that it is very cost effective therapy with a better output.
Post a Comment